IMMUNOVANT INC (IMVT) Stock Analyst Ratings
NASDAQ:IMVT • US45258J1025
26.65 USD
+0.37 (+1.41%)
At close: Feb 18, 2026
26.65 USD
0 (0%)
After Hours: 2/18/2026, 8:00:02 PM
ChartMill assigns a Buy % Consensus number of 83% to IMVT. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 40.26. This target is 51.05% above the current price.
- IMVT was analyzed by 23 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IMVT.
- In the previous month the buy percentage consensus was at a similar level.
- IMVT was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-09 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-08 | Truist Securities | Maintains | Hold -> Hold |
| 2026-01-06 | Wolfe Research | Upgrade | Peer Perform -> Outperform |
| 2025-12-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-10-14 | Truist Securities | Initiate | Hold |
| 2025-09-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-12 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-28 | UBS | Maintains | Neutral -> Neutral |
| 2025-04-22 | UBS | Downgrade | Buy -> Neutral |
| 2025-03-20 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-15 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-03 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2024-12-19 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | Raymond James | Reiterate | Outperform |
| 2024-10-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-09-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-13 | UBS | Maintains | Buy -> Buy |
| 2024-08-08 | JP Morgan | Maintains | Overweight -> Overweight |
IMMUNOVANT INC / IMVT FAQ
What do analysts expect the price target to be for IMMUNOVANT INC (IMVT)?
23 analysts have analysed IMVT and the average price target is 40.26 USD. This implies a price increase of 51.05% is expected in the next year compared to the current price of 26.65.
What is the consensus rating for IMMUNOVANT INC (IMVT) stock?
The consensus rating for IMMUNOVANT INC (IMVT) is 83.4783 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed IMMUNOVANT INC (IMVT)?
The number of analysts covering IMMUNOVANT INC (IMVT) is 23.